Bicycle Therapeutics Plc (BCYC) Stock Price & Analysis
Bicycle Therapeutics Plc (BCYC) rose 1.46% to USD 4.17 as of June 10, 2026 at 02:19 UTC, according to Nexqual real-time market data.
BCYC last closed at USD 4.11; the session ranged USD 3.99–4.22 on volume of 670,308 shares. Market capitalization is $291.11M, with a 52-week range of USD 3.99–9.36 (NMS). Source: Nexqual, June 10, 2026 at 02:19 UTC.
Key Statistics (as of June 10, 2026 at 02:19 UTC)
| Price | USD 4.17 |
|---|---|
| Change | ▲ 1.46% (up) |
| Previous Close | USD 4.11 |
| Open | USD 4.12 |
| Day Range | USD 3.99 – 4.22 |
| 52-Week Range | USD 3.99 – 9.36 |
| Volume | 670,308 shares |
| Market Cap | $291.11M |
| Exchange | NMS |
Technical Analysis (BCYC)
Nexqual's technical model rates BCYC "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.06 (neutral) |
| vs SMA50 | Below (USD 4.73) |
| MACD | -0.16 (negative) |
Analyst Ratings (BCYC)
Wall Street analysts rate BCYC "Buy" based on 9 analysts, with a mean price target of USD 12.11 (range USD 5–36), per Nexqual as of June 10, 2026 at 02:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 12.11 |
| High Target | USD 36 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 7 / 4 / 0 |
Earnings (BCYC)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD -0.58 |
| Revenue Estimate | $4.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.87 vs est -0.67 ▼ miss |
| 2025-12-31 | USD -0.29 vs est -0.95 ▲ beat |
| 2025-09-30 | USD -0.85 vs est -1.07 ▲ beat |
| 2025-06-30 | USD -1.14 vs est -0.93 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financials & Fundamentals (BCYC)
| Total Revenue | $63.50M |
|---|---|
| Revenue Growth (YoY) | -91.10% |
| Gross Margin | -244.54% |
| Operating Margin | -7382.41% |
| Profit Margin | +0.00% |
| ROE | -33.84% |
| Debt / Equity | 2.77 |
| Current Ratio | 12.66 |
| Total Cash | $559.47M |
| Total Debt | $15.34M |
| Free Cash Flow | $-109.75M |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financial Health Score (BCYC)
Nexqual rates Bicycle Therapeutics Plc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:19 UTC.
| Growth | Strong — Revenue +106% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $559M cash vs $15M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$110M, burning cash |
| Efficiency | Critical — ROE -34%, ROA -19.4% |
Ownership (BCYC)
| Insider Ownership | +4.49% |
|---|---|
| Institutional Ownership | +73.65% |
| Shares Outstanding | 50.37M |
| Short % of Float | +7.36% |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Leadership (BCYC)
Bicycle Therapeutics Plc is led by Kevin Lee (age 57), CEO & Executive Director, per Nexqual as of June 10, 2026 at 02:19 UTC.
| CEO & Executive Director | Kevin Lee (age 57) |
|---|---|
| Co-Founder & Independent Non-Executive Director | Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE (age 74) |
| Chief Scientific Officer | Michael Skynner B.sc. (age 56) |
| Chief Financial Officer | Travis Thompson (age 45) |
| Chief Operating Officer | Jennifer Perry Pharm.D. (age 51) |
Major Backers & Investors (BCYC)
Notable institutional backers of Bicycle Therapeutics Plc include Baker Bros. Advisors, LP, FCPM III Services B.V., Armistice Capital, LLC, according to Nexqual as of June 10, 2026 at 02:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 21.61% |
| FCPM III Services B.V. | 6.89% |
| Armistice Capital, LLC | 6.75% |
| Long Focus Capital Management, LLC | 6.57% |
| Acadian Asset Management. LLC | 3.91% |
| Siren, L.L.C. | 3.1% |
| GSK plc | 3.04% |
| Principal Financial Group, Inc. | 2.33% |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
From Bicycle Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
- In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical.
- Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.
- It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| ARVN | Arvinas, Inc. | USD 7.21 | ▼ 2.83% |
| STRO | Sutro Biopharma, Inc. | USD 25.79 | ▼ 1.15% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:19 UTC. This page is informational and not investment advice.